BioXcel Therapeutics Announces Executive Changes and Wind-Down Process
BioXcel Therapeutics terminated four officers and appointed Samir Saleem as president and secretary as part of a company wind-down.
Economy · News reference
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
U.S. stocks mixed as Dow and S&P fell despite strong August job gains; tech rose, energy slid, and oil, gold and silver declined.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Teva Completes Acquisition of Neuroscience Assets from BioXcel Therapeutics
Teva Pharmaceuticals International GmbH has acquired worldwide rights to BXCL501 and IGALMI from BioXcel Therapeutics, Inc. through a court-supervised bankruptcy sale.
Immuron Reports Unaudited Sales Growth for Q1 FY27
Immuron Limited announced double-digit sales growth for the quarter ending September 30, 2026, driven by strong performance of its Travelan product in Australia.
12 Industrials Stocks Moving In Monday's Intraday Session
Gainers GrafTech International (NYSE:EAF) stock moved upwards by 33.1% to $11.32 during Monday's regular session. The company's market cap stands at $200.3 million. The company's, Q3 earnings came out
Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference
Immuron Limited announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on October 28, 2026.
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
Immuron Limited announced that Chief Executive Officer Steven Lydeamore will present virtually at the Emerging Growth Conference on October 28, 2026. The presentation will focus on the company's biopharmaceutical pipeline, including its lead product Travelan® for travelers' diarrhea, IMM-529 for Clostridioides difficile infection, and the ProIBS® distribution agreement in Australia and New Zealand.